IVD Recalls Should Be Viewed As “Norm” Rather Than “Exception” – Gutman
This article was originally published in The Gray Sheet
Executive Summary
Recalls should be viewed as a mechanism to improve quality control systems in companies and laboratories, according to Office of In Vitro Diagnostic Device Evaluation & Safety Director Steve Gutman
You may also be interested in...
Compliance Office Sees Decline In Overall Recalls, Uptick In Class I
The upswing of Class I recalls in fiscal 2004 is not necessarily a cause for alarm, CDRH Office of Compliance Director Tim Ulatowski suggested at the Indiana Medical Device Manufacturers Council annual meeting in Indianapolis Oct. 26
Compliance Office Sees Decline In Overall Recalls, Uptick In Class I
The upswing of Class I recalls in fiscal 2004 is not necessarily a cause for alarm, CDRH Office of Compliance Director Tim Ulatowski suggested at the Indiana Medical Device Manufacturers Council annual meeting in Indianapolis Oct. 26
IVD Office Ponders Future Of LabSun As Surveillance Pilot Ends
CDRH's Office of In Vitro Diagnostic Device Evaluation & Safety plans to meet in early May to discuss rolling its LabSun pilot into the device center's larger MedSun adverse event surveillance program